By Associate Professor Suzanne Jean Hodgkinson

Journal articles

Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H, 2024, 'Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom', Journal of medical economics, 27, pp. 109 - 125, http://dx.doi.org/10.1080/13696998.2023.2293379

Hardy TA; Aouad P; Barnett MH; Blum S; Broadley S; Carroll WM; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; McCombe P; Parratt J; Plummer C; Van der Walt A; Martel K; Walker RA, 2024, 'Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme', Multiple Sclerosis Journal - Experimental, Translational and Clinical, 10, http://dx.doi.org/10.1177/20552173231226106

Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; De Gans K; McCombe PA; Ampapa R; Van Der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T, 2023, 'Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: Causal inference to emulate a multiarm randomised trial', Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 1004 - 1011, http://dx.doi.org/10.1136/jnnp-2023-331499

Sharmin S; Roos I; Simpson-Yap S; Malpas C; Sánchez MM; Ozakbas S; Horakova D; Havrdova EK; Patti F; Alroughani R; Izquierdo G; Eichau S; Boz C; Zakaria M; Onofrj M; Lugaresi A; Weinstock-Guttman B; Prat A; Girard M; Duquette P; Terzi M; Amato MP; Karabudak R; Grand’Maison F; Khoury SJ; Grammond P; Lechner-Scott J; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Turkoglu R; Altintas A; Maimone D; Kermode A; Shalaby N; Pesch VV; Butler E; Sidhom Y; Gouider R; Mrabet S; Gerlach O; Soysal A; Barnett M; Kuhle J; Hughes S; Sa MJ; Hodgkinson S; Oreja-Guevara C; Ampapa R; Petersen T; Ramo-Tello C; Spitaleri D; McCombe P; Taylor B; Prevost J; Foschi M; Slee M; McGuigan C; Laureys G; Hijfte LV; de Gans K; Solaro C; Oh J; Macdonell R; Aguera-Morales E; Singhal B; Gray O; Garber J; Wijmeersch BV; Simu M; Castillo-Triviño T; Sanchez-Menoyo JL; Khurana D; Al-Asmi A; Al-Harbi T; Deri N; Fragoso Y; Lalive PH; Sinnige LGF; Shaw C; Shuey N; Csepany T; Sempere AP; Moore F; Decoo D; Willekens B; Gobbi C; Massey J; Hardy T; Parratt J; Kalincik T, 2023, 'The risk of secondary progressive multiple sclerosis is geographically determined but modifiable', Brain, 146, pp. 4633 - 4644, http://dx.doi.org/10.1093/brain/awad218

Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri DLA; Pesch VV; Horakova D; Ampapa R; Patti F; MacDonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H, 2023, 'A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry', Neurodegenerative Disease Management, 13, pp. 215 - 221, http://dx.doi.org/10.2217/nmt-2023-0005

Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; MacDonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trněný M; Kozak T; Van Der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; Van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; De Gans K; Kermode A, 2023, 'Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis', JAMA Neurology, 80, pp. 702 - 713, http://dx.doi.org/10.1001/jamaneurol.2023.1184

Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; MacDonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; Van Der Walt A; Butzkueven H, 2023, 'Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation', JAMA Neurology, 80, pp. 739 - 748, http://dx.doi.org/10.1001/jamaneurol.2023.1542

Daruwalla C; Shaygannejad V; Ozakbas S; Havrdova EK; Horakova D; Alroughani R; Boz C; Patti F; Onofrj M; Lugaresi A; Eichau S; Girard M; Prat A; Duquette P; Yamout B; Khoury SJ; Sajedi SA; Turkoglu R; Altintas A; Skibina O; Buzzard K; Grammond P; Karabudak R; van der Walt A; Butzkueven H; Maimone D; Lechner-Scott J; Soysal A; John N; Prevost J; Spitaleri D; Ramo-Tello C; Gerlach O; Iuliano G; Foschi M; Ampapa R; van Pesch V; Barnett M; Shalaby N; D’hooghe M; Kuhle J; Sa MJ; Fabis-Pedrini M; Kermode A; Mrabet S; Gouider R; Hodgkinson S; Laureys G; Van Hijfte L; Macdonell R; Oreja-Guevara C; Cristiano E; McCombe P; Sanchez-Menoyo JL; Singhal B; Blanco Y; Hughes S; Garber J; Solaro C; McGuigan C; Taylor B; de Gans K; Habek M; Al-Asmi A; Mihaela S; Castillo Triviño T; Al-Harbi T; Rojas JI; Gray O; Khurana D; Van Wijmeersch B; Grigoriadis N; Inshasi J; Oh J; Aguera-Morales E; Fragoso Y; Moore F; Shaw C; Baghbanian SM; Shuey N; Willekens B; Hardy TA; Decoo D; sempere AP; Field D; Wynford-Thomas R; Cunniffe NG; Roos I; Malpas CB; Coles AJ; Kalincik T; Brown JWL, 2023, 'Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis', Multiple Sclerosis Journal, 29, pp. 875 - 883, http://dx.doi.org/10.1177/13524585231151951

Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Havrdova EK; Patti F; Shaygannejad V; Ozakbas S; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Girard M; Duquette P; Terzi M; Boz C; Grand'Maison F; Hamdy S; Sola P; Ferraro D; Grammond P; Turkoglu R; Buzzard K; Skibina O; Yamout B; Altintas A; Gerlach O; van Pesch V; Blanco Y; Maimone D; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Barnett M; Hughes S; Sa MJ; Solaro C; Kappos L; Ramo-Tello C; Cristiano E; Hodgkinson S; Spitaleri D; Soysal A; Petersen T; Slee M; Butler E; Granella F; de Gans K; McCombe P; Ampapa R; Van Wijmeersch B; van der Walt A; Butzkueven H; Prevost J; Sinnige LGF; Sanchez-Menoyo JL; Vucic S; Laureys G; Van Hijfte L; Khurana D; Macdonell R; Gouider R; Castillo-Triviño T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Deri N; Al-Harbi T; Fragoso Y; Csepany T; Perez Sempere A; Trevino-Frenk I; Schepel J; Moore F; Kalincik T, 2023, 'Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis', European Journal of Neurology, 30, pp. 1014 - 1024, http://dx.doi.org/10.1111/ene.15706

Roos I; Diouf I; Sharmin S; Horakova D; Havrdova EK; Patti F; Shaygannejad V; Ozakbas S; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Girard M; Duquette P; Terzi M; Boz C; Grand’Maison F; Sola P; Ferraro D; Grammond P; Turkoglu R; Buzzard K; Skibina O; Yamou B; Altintas A; Gerlach O; van Pesch V; Blanco Y; Maimone D; Lechner-Scott J; Bergamaschi R; Karabudak R; McGuigan C; Cartechini E; Barnett M; Hughes S; Sa MJ; Solaro C; Ramo-Tello C; Hodgkinson S; Spitaleri D; Soysal A; Petersen T; Granella F; de Gans K; McCombe P; Ampapa R; Van Wijmeersch B; van der Walt A; Butzkueven H; Prevost J; Sanchez-Menoyo JL; Laureys G; Gouider R; Castillo-Triviño T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Deri N; Al-Harbi T; Fragoso Y; Csepany T; Sempere AP; Trevino-Frenk I; Schepel J; Moore F; Malpas C; Kalincik T, 2023, 'Comparative effectiveness in multiple sclerosis: A methodological comparison', Multiple Sclerosis Journal, 29, pp. 326 - 332, http://dx.doi.org/10.1177/13524585231151394

Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri DLA; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H, 2023, 'Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry', Multiple Sclerosis Journal, 29, pp. 221 - 235, http://dx.doi.org/10.1177/13524585221137502

Wiendl H; Schmierer K; Hodgkinson S; Derfuss T; Chan A; Sellebjerg F; Achiron A; Montalban X; Prat A; De Stefano N; Barkhof F; Leocani L; Vermersch P; Chudecka A; Mwape C; Holmberg KH; Boschert U; Roy S, 2023, 'Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy', Neurology: Neuroimmunology and NeuroInflammation, 10, http://dx.doi.org/10.1212/NXI.0000000000200048

Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B, 2023, 'Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence', Multiple Sclerosis and Related Disorders, 69, http://dx.doi.org/10.1016/j.msard.2022.104459

Zhong M; van der Walt A; Monif M; Hodgkinson S; Eichau S; Kalincik T; Lechner-Scott J; Buzzard K; Skibina O; Van Pesch V; Butler E; Prevost J; Girard M; Oh J; Butzkueven H; Jokubaitis V, 2023, 'Prediction of relapse activity when switching to cladribine for multiple sclerosis', Multiple Sclerosis Journal, 29, pp. 119 - 129, http://dx.doi.org/10.1177/13524585221111677

De Stefano N; Achiron A; Barkhof F; Chan A; Derfuss T; Hodgkinson S; Leocani L; Montalban X; Prat A; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Smyk A; Gardner L, 2023, 'Early onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study', Multiple Sclerosis and Related Disorders, 71, pp. 104322 - 104322, http://dx.doi.org/10.1016/j.msard.2022.104322

Hodgkinson S; Derfuss T; Sellebjerg F; Vermersch P; Barkhof F; Schmierer K; De Stefano N; Achiron A; Leocani L; Chan A; Montalban X; Prat A; Kloetgen A; Jin H; Gardner L; Jarvinen E; Wiendl H, 2023, 'Investigation of Changes in Lymphocyte Subset Counts and their Relationship with MRI Outcomes in the Magnify-MS Study', Multiple Sclerosis and Related Disorders, 80, pp. 105237 - 105237, http://dx.doi.org/10.1016/j.msard.2023.105237

Cordato D; Blair C; Thomas P; Firtko A; Miller M; Edwards LS; Thomas J; Balabanski AH; Dos Santos A; Lin L; Hodgkinson S; Cappelen-Smith C; Beran RG; McDougall A; Parsons M, 2022, 'Cerebrovascular Disease Profiles of Culturally and Linguistically Diverse Communities in South Western Sydney and New South Wales', Cerebrovascular Diseases, 51, pp. 744 - 754, http://dx.doi.org/10.1159/000524242

Cheung J; Zahorowska B; Suranyi M; Wong JKW; Diep J; Spicer ST; Verma ND; Hodgkinson SJ; Hall BM, 2022, 'CD4+CD25+ T regulatory cells in renal transplantation', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1017683

Roos I; Malpas C; Leray E; Casey R; Horakova D; Havrdova EK; Debouverie M; Patti F; De Seze J; Izquierdo G; Eichau S; Edan G; Prat A; Girard M; Ozakbas S; Grammond P; Zephir H; Ciron J; Maillart E; Moreau T; Amato MP; Labauge P; Alroughani R; Buzzard K; Skibina O; Terzi M; Laplaud DA; Berger E; Grand'maison F; Lebrun-Frenay C; Cartechini E; Boz C; Lechner-Scott J; Clavelou P; Stankoff B; Prevost J; Kappos L; Pelletier J; Shaygannejad V; Yamout BI; Khoury SJ; Gerlach O; Spitaleri DLA; Van Pesch V; Gout O; Turkoglu R; Heinzlef O; Thouvenot E; McCombe PA; Soysal A; Bourre B; Slee M; Castillo-Trivino T; Bakchine S; Ampapa R; Butler EG; Wahab A; MacDonell RA; Aguera-Morales E; Cabre P; Ben NH; Van Der Walt A; Laureys G; Van Hijfte L; Ramo-Tello CM; Maubeuge N; Hodgkinson S; Sánchez-Menoyo JL; Barnett MH; Labeyrie C; Vucic S; Sidhom Y; Gouider R; Csepany T; Sotoca J; De Gans K; Al-Asmi A; Fragoso YD; Vukusic S; Butzkueven H; Kalincik T, 2022, 'Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis', Neurology, 99, pp. E1926 - E1944, http://dx.doi.org/10.1212/WNL.0000000000201029

Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; MacDonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; Van Der Walt A; Butzkueven H, 2022, 'Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis', Journal of Neurology, Neurosurgery and Psychiatry, 93, pp. 1330 - 1337, http://dx.doi.org/10.1136/jnnp-2022-330104

Sharmin S; Bovis F; Malpas C; Horakova D; Havrdova E; Izquierdo G; Eichau S; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Terzi M; Gerlach O; Alroughani R; Boz C; Shaygannejad V; van Pesch V; Cartechini E; Kappos L; Lechner-Scott J; Bergamaschi R; Turkoglu R; Solaro C; Iuliano G; Granella F; Van Wijmeersch B; Spitaleri D; Slee M; McCombe P; Prevost J; Ampapa R; Ozakbas S; Sanchez-Menoyo J; Soysal A; Vucic S; Petersen T; de Gans K; Butler E; Hodgkinson S; Sidhom Y; Gouider R; Cristiano E; Castillo-Triviño T; Saladino M; Barnett M; Moore F; Rozsa C; Yamout B; Skibina O; van der Walt A; Buzzard K; Gray O; Hughes S; Sempere AP; Singhal B; Fragoso Y; Shaw C; Kermode A; Taylor B; Simo M; Shuey N; Al-Harbi T; Macdonell R; Dominguez JA; Csepany T; Sirbu C; Sormani MP; Butzkueven H; Kalincik T, 2022, 'Confirmed disability progression as a marker of permanent disability in multiple sclerosis', European Journal of Neurology, 29, pp. 2321 - 2334, http://dx.doi.org/10.1111/ene.15406

De Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S, 2022, 'Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS', Neurology: Neuroimmunology and NeuroInflammation, 9, pp. E1187, http://dx.doi.org/10.1212/NXI.0000000000001187

Vitkova M; Diouf I; Malpas C; Horakova D; Kubala Havrdova E; Patti F; Ozakbas S; Izquierdo G; Eichau S; Shaygannejad V; Onofrj M; Lugaresi A; Alroughani R; Prat A; Larochelle C; Girard M; Duquette P; Terzi M; Boz C; Grand'maison F; Sola P; Ferraro D; Grammond P; Butzkueven H; Buzzard K; Skibina O; Yamout BI; Karabudak R; Gerlach O; Lechner-Scott J; Maimone D; Bergamaschi R; Van Pesch V; Iuliano G; Cartechini E; José Sà M; Ampapa R; Barnett M; Hughes SE; Ramo-Tello CM; Hodgkinson S; Spitaleri DLA; Petersen T; Butler EG; Slee M; McGuigan C; McCombe PA; Granella F; Cristiano E; Prevost J; Taylor BV; Sãnchez-Menoyo JL; Laureys G; Van Hijfte L; Vucic S; MacDonell RA; Gray O; Olascoaga J; Deri N; Fragoso YD; Shaw C; Kalincik T, 2022, 'Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study', Neurology, 98, pp. E2401 - E2412, http://dx.doi.org/10.1212/WNL.0000000000200545

Butzkueven H; Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri DLA; Van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong S, 2022, 'Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry (P12-4.003)', Neurology, 98, http://dx.doi.org/10.1212/wnl.98.18_supplement.1373

Zhong M; van der Walt A; Stankovich J; Kalincik T; Buzzard K; Skibina O; Boz C; Hodgkinson S; Slee M; Lechner-Scott J; Macdonell R; Prevost J; Kuhle J; Laureys G; Van Hijfte L; Alroughani R; Kermode AG; Butler E; Barnett M; Eichau S; van Pesch V; Grammond P; McCombe P; Karabudak R; Duquette P; Girard M; Taylor B; Yeh W; Monif M; Gresle M; Butzkueven H; Jokubaitis VG, 2022, 'Prediction of multiple sclerosis outcomes when switching to ocrelizumab', Multiple Sclerosis Journal, 28, pp. 958 - 969, http://dx.doi.org/10.1177/13524585211049986

Hall BM; Verma ND; Tran GT; Hodgkinson SJ, 2022, 'Transplant Tolerance, Not Only Clonal Deletion', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.810798

Malpas CB; Roos I; Sharmin S; Buzzard K; Skibina O; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T, 2022, 'Multiple Sclerosis Relapses Following Cessation of Fingolimod', Clinical Drug Investigation, 42, pp. 355 - 364, http://dx.doi.org/10.1007/s40261-022-01129-7

Bukhari W; Khalilidehkordi E; Mason DF; Barnett MH; Taylor BV; Fabis-Pedrini M; Kermode AG; Subramanian S; Waters P; Broadley SA; Broadley SA; Abernethy D; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brilot F; Brownlee WJ; Bundell CS; Butzkueven H; Carroll WM; Chen C; Clarke L; Coulthard A; Dale RC; Das C; Dear K; Fulcher D; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Jimenez Sanchez S; Kilpatrick TJ; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonell RAL; Marriott MP; McCombe PA; O’Gorman C; Parratt JDE; Pender MP; Pereira J; Pollard JD; Prain KM; Ramanathan S; Reddell SW; Shaw C; Silvestrini RA; Slee M; Spies J; Stankovich J; Sutton I; Vincent A; Vucic S; Walsh M; Willoughby E; Wong RC; Woodhall M; Yiu EM, 2022, 'NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand', Journal of Neurology, 269, pp. 836 - 845, http://dx.doi.org/10.1007/s00415-021-10665-9

Clarke L; Bukhari W; O'Gorman CM; Khalilidehkordi E; Arnett S; Woodhall M; Prain KM; Parratt JDE; Barnett MH; Marriott MP; McCombe PA; Sutton I; Boggild M; Brownlee W; Carroll WM; Hodgkinson S; Macdonell RAL; Mason DF; Pereira J; Slee M; Das C; Henderson APD; Kermode AG; Lechner-Scott J; Waters P; Sun J; Broadley SA, 2022, 'Response to treatment in NMOSD: the Australasian experience', Multiple Sclerosis and Related Disorders, 58, http://dx.doi.org/10.1016/j.msard.2021.103408

Verma ND; Lam AD; Chiu C; Tran GT; Hall BM; Hodgkinson SJ, 2021, 'Multiple sclerosis patients have reduced resting and increased activated CD4⁺CD25⁺FOXP3⁺T regulatory cells', Scientific Reports, 11, http://dx.doi.org/10.1038/s41598-021-88448-5

Hall BM; Hall RM; Tran GT; Robinson CM; Wilcox PL; Rakesh PK; Wang C; Sharland AF; Verma ND; Hodgkinson SJ, 2021, 'Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4⁺CD25⁺ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor', Frontiers in Immunology, 12, http://dx.doi.org/10.3389/fimmu.2021.714838

Maltby VE; Lea RA; Monif M; Fabis-Pedrini MJ; Buzzard K; Kalincik T; Kermode AG; Taylor B; Hodgkinson S; McCombe P; Butzkueven H; Barnett M; Lechner-Scott J, 2021, 'Efficacy of Cladribine Tablets as a Treatment for People with Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-Term Efficacy and Biomarker Australian Study)', JMIR Research Protocols, 10, http://dx.doi.org/10.2196/24969

Clarke L; Arnett S; Bukhari W; Khalilidehkordi E; Jimenez Sanchez S; O'Gorman C; Sun J; Prain KM; Woodhall M; Silvestrini R; Bundell CS; Abernethy DA; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brownlee W; Butzkueven H; Carroll WM; Chen C; Coulthard A; Dale RC; Das C; Fabis-Pedrini MJ; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Kilpatrick TJ; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonell RAL; Mason DF; McCombe PA; Pereira J; Pollard JD; Ramanathan S; Reddel SW; Shaw CP; Spies JM; Stankovich J; Sutton I; Vucic S; Walsh M; Wong RC; Yiu EM; Barnett MH; Kermode AGK; Marriott MP; Parratt JDE; Slee M; Taylor BV; Willoughby E; Brilot F; Vincent A; Waters P; Broadley SA, 2021, 'MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis', Frontiers in Neurology, 12, http://dx.doi.org/10.3389/fneur.2021.722237

Yeh WZ; Widyastuti PA; Van der Walt A; Stankovich J; Havrdova E; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout BI; Lechner-Scott J; Sola P; Skibina OG; Barnett M; Onofrj M; Sá MJ; McCombe PA; Grammond P; Ampapa R; Grand'Maison F; Bergamaschi R; Spitaleri DLA; Van Pesch V; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Gresle M; Uher T; Maimone D; Turkoglu R; Hupperts RMM; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell RA; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis VG, 2021, 'Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis', Neurology, 96, pp. E2989 - E3002, http://dx.doi.org/10.1212/WNL.0000000000012084

Vitkova M; Diouf I; Malpas C; Horakova D; Havrdova EK; Patti F; Ozakbas S; Ayuso GI; Madueño SE; Shaygannejad V; Onofrj M; Lugaresi A; Alroughani R; Prat A; Larochelle C; Girard M; Duquette P; Terzi M; Boz C; Grand’Maison F; Sola P; Ferraro D; Grammond P; Butzkueven H; Buzzard K; Skibina O; Yamout B; Karabudak R; Gerlach OHH; Lechner-Scott J; Maimone D; Bergamaschi R; Van Pesch V; Iuliano G; Cartechini E; Sá MJ; Ampapa R; Barnett M; Hughes S; Ramo-Tello C; Hodgkinson S; Spitareli D; Petersen T; Butler E; Slee M; McGuigan C; McCombe P; Granella F; Cristiano E; Prevost J; Taylor B; Sanchez-Menoyo JL; Laureys G; Van Hijfte L; Vucic S; Macdonell R; Gray O; Urtaza FJO; Deri N; Fragoso Y; Shaw C; Kalincik T, 2021, 'Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis (2554)', Neurology, 96, http://dx.doi.org/10.1212/wnl.96.15_supplement.2554

Wiendl H; Schmierer K; Hodgkinson S; Derfuss T; Chan A; Sellebjerg F; Achiron A; Montalban X; Prat A; De Stefano N; Barkhof F; Leocani L; Vermersch P; Chudecka A; Roy S; Boschert U, 2021, 'Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study (2235)', Neurology, 96, http://dx.doi.org/10.1212/wnl.96.15_supplement.2235

Harding-Forrester S; Roos I; Sharmin S; Diouf I; Malpas C; Nguyen A-L; Moradi N; Horáková D; Havrdová EK; Patti F; Ayuso GI; Madueño SE; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Grand’Maison F; Weinstock-Guttman B; Amato MP; Grammond P; Gerlach O; Ozakbas S; Sola P; Ferraro D; Butzkueven H; Lechner-Scott J; Boz C; Alroughani R; Van Pesch V; Cartechini E; Terzi M; Maimone D; Ramo-Tello C; Spitaleri DLA; Kappos L; Yamout B; Sá MJ; Slee M; Morgado YB; Bergamaschi R; Butler E; Iuliano G; Granella F; Sidhom Y; Gouider R; Ampapa R; Van Wijmeersch B; Karabudak R; Prevost J; Sánchez-Menoyo JL; De Gans K; McCombe P; Castillo-Triviño T; Macdonell R; Altintas A; Laureys G; Van Hijfte L; Van Der Walt A; Vucic S; Türkoǧlu R; Barnett M; Cristiano E; Zakaria M; Shaygannejad V; Hodgkinson S; Soysal A; Buzzard K; Skibina O; Kalincik T, 2021, 'Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)', Neurology, 96, http://dx.doi.org/10.1212/wnl.96.15_supplement.2901

Butzkueven H; Spelman T; Hodgkinson S; Kalincik T; Buzzard K; Skabina O; Madueño SE; Ayuso GI; Van der Walt A; Grand-Maison F; Butler E; Prevost J; McCombe P; Oh J; Macdonell R; Lechner-Scott J; Van Pesch V; Duquette P; Prat A; Girard M; Kermode A; Fabris J, 2021, 'Real-world Experience with Cladribine Tablets in the MSBase Registry (2942)', Neurology, 96, http://dx.doi.org/10.1212/wnl.96.15_supplement.2942

De Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S, 2021, 'Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis (1921)', Neurology, 96, http://dx.doi.org/10.1212/wnl.96.15_supplement.1921

Diouf I; Malpas C; Horakova D; Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Ayuso GI; Madueño SE; Zakaria M; Onofrj M; Lugaresi A; Alroughani R; Prat A; Girard M; Duquette P; Terzi M; Boz C; Grand’Maison F; Hamdy S; Sola P; Ferraro D; Grammond P; Turkoglu R; Butzkueven H; Yamout B; Altintas A; Van Pesch V; Maimone D; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Barnett M; Hughes S; Sa MJ; Kappos L; Ramo-Tello C; Cristiano E; Hodgkinson S; Spitaleri DLA; Soysal A; Petersen T; Slee M; Butler E; Granella F; Verheul F; McCombe P; Ampapa R; Skibina O; Prevost J; Sinnige L; Sanchez-Menoyo JL; Vucic S; Laureys G; Van Hijfte L; Khurana D; Macdonell R; Castillo-Triviño T; Gray O; Aguera-Morales E; Kister I; Shaw C; Deri N; Al-Harbi T; Fragoso Y; Csepany T; Sempere A; Kalincik T, 2021, 'Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)', Neurology, 96, http://dx.doi.org/10.1212/wnl.96.15_supplement.4107

Lizak N; Hodgkinson S; Butler E; Lechner-Scott J; Slee M; McCombe PA; Shaw C; Skibina O; Vucic S; Shuey N; Barnett MH; Parratt J; Butzkueven H; Jack D; Fabris J; Kalincik T, 2021, 'Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy', Multiple Sclerosis Journal, 27, pp. 465 - 474, http://dx.doi.org/10.1177/1352458520921087

Kalincik T; Diouf I; Sharmin S; Malpas C; Spelman T; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Jokubaitis V; van der Walt A; Grand'Maison F; Sola P; Ferraro D; Shaygannejad V; Alroughani R; Hupperts R; Terzi M; Boz C; Lechner-Scott J; Pucci E; Van Pesch V; Granella F; Bergamaschi R; Spitaleri D; Slee M; Vucic S; Ampapa R; McCombe P; Ramo-Tello C; Prevost J; Olascoaga J; Cristiano E; Barnett M; Saladino ML; Sanchez-Menoyo JL; Hodgkinson S; Rozsa C; Hughes S; Moore F; Shaw C; Butler E; Skibina O; Gray O; Kermode A; Csepany T; Singhal B; Shuey N; Piroska I; Taylor B; Simo M; Sirbu CA; Sas A; Butzkueven H, 2021, 'Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years', Neurology, 96, pp. e783 - e797, http://dx.doi.org/10.1212/WNL.0000000000011242

Chan A; Rose J; Alvarez E; Bar-Or A; Butzkueven H; Fox RJ; Gold R; Gudesblatt M; Haartsen J; Spelman T; Wright K; Ferraro D; Sola P; Hodgkinson S; Kalincik T; Lechner-Scott J; McGuigan C; Spach K; Chen C; Fam S; Wu F; Miller C, 2020, 'Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS', Neurology: Clinical Practice, 10, pp. 510 - 519, http://dx.doi.org/10.1212/CPJ.0000000000000800

Roos I; Leray E; Frascoli F; Casey R; Brown WJL; Horakova D; Havrdova EK; Trojano M; Patti F; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Prat A; Girard M; Grammond P; Sola P; Ferraro D; Ozakbas S; Bergamaschi R; Sá MJ; Cartechini E; Boz C; Granella F; Hupperts R; Terzi M; Lechner-Scott J; Spitaleri D; van Pesch V; Soysal A; Olascoaga J; Prevost J; Aguera-Morales E; Slee M; Csepany T; Turkoglu R; Sidhom Y; Gouider R; van Wijmeersch B; McCombe P; Macdonell R; Coles A; Malpas CB; Butzkueven H; Vukusic S; Kalincik T; Duquette P; Grand'Maison F; Iuliano G; Ramo-Tello C; Solaro C; Cabrera-Gomez JA; Rio ME; Bolaños RF; Shaygannejad V; Oreja-Guevara C; Sanchez-Menoyo JL; Petersen T; Altintas A; Barnett M; Flechter S; Fragoso Y; Amato MP; Moore F; Ampapa R; Verheul F; Hodgkinson S; Cristiano E; Yamout B; Laureys G; Dominguez JA; Zwanikken C; Deri N; Dobos E; Vrech C; Butler E; Rozsa C; Petkovska-Boskova T; Karabudak R; Rajda C; Alkhaboori J; Saladino ML; Shaw C; Shuey N; Vucic S; Sempere AP; Campbell J; Piroska I; Taylor B; van der Walt A; Kappos L; Roullet E; Gray O; Simo M; Sirbu CA; Brochet B; Cotton F; de Sèze J; Dion A; Douek P, 2020, 'Delay from treatment start to full effect of immunotherapies for multiple sclerosis', Brain, 143, pp. 2742 - 2756, http://dx.doi.org/10.1093/brain/awaa231

Khalilidehkordi E; Clarke L; Arnett S; Bukhari W; Jimenez Sanchez S; O'Gorman C; Sun J; Prain KM; Woodhall M; Silvestrini R; Bundell CS; Abernethy D; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brown M; Brownlee W; Butzkueven H; Carroll WM; Chen C; Coulthard A; Dale RC; Das C; Fabis-Pedrini MJ; Fulcher D; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Kilpatrick TJ; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonell RAL; Mason DF; McCombe PA; Pereira J; Pollard JD; Ramanathan S; Reddel SW; Shaw C; Spies J; Stankovich J; Sutton I; Vucic S; Walsh M; Wong RC; Yiu EM; Barnett MH; Kermode AG; Marriott MP; Parratt J; Slee M; Taylor BV; Willoughby E; Brilot F; Vincent A; Waters P; Broadley SA, 2020, 'Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation', Frontiers in Neurology, 11, http://dx.doi.org/10.3389/fneur.2020.00537

Bukhari W; Clarke L; O’Gorman C; Khalilidehkordi E; Arnett S; Prain KM; Woodhall M; Silvestrini R; Bundell CS; Ramanathan S; Abernethy D; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brownlee W; Butzkueven H; Carroll WM; Chen C; Coulthard A; Dale RC; Das C; Dear K; Fabis-Pedrini MJ; Fulcher D; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Jimenez-Sanchez S; Kilpatrick TJ; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonnell RAL; Mason DF; McCombe PA; Pereira J; Pollard JD; Reddel SW; Shaw C; Spies J; Stankovich J; Sutton I; Vucic S; Walsh M; Wong RC; Yiu EM; Barnett MH; Kermode AG; Marriott MP; Parratt J; Slee M; Taylor BV; Willoughby E; Wilson RJ; Brilot F; Vincent A; Waters P; Broadley SA, 2020, 'The clinical profile of NMOSD in Australia and New Zealand', Journal of Neurology, 267, pp. 1431 - 1443, http://dx.doi.org/10.1007/s00415-020-09716-4

Tran GT; Hodgkinson SJ; Carter N; Verma ND; Robinson CM; Plain KM; Nomura M; Hall BM, 2020, 'Autoantigen specific IL-2 activated CD4⁺CD25⁺T regulatory cells inhibit induction of experimental autoimmune neuritis', Journal of Neuroimmunology, 341, http://dx.doi.org/10.1016/j.jneuroim.2020.577186

Maltby V; Lydon A; Monif M; Kilpatrick T; Butzkueven H; Taylor B; McCombe P; Hodgkinson S; Fabis-Pedrini M; Kermode A; Barnett M; Kalincik T; Lechner-Scott J, 2020, 'Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS) (5285)', Neurology, 94, http://dx.doi.org/10.1212/wnl.94.15_supplement.5285

Sharmin S; Bovis F; Malpas C; Horakova D; Havrdova E; Ayuso GI; Eichau S; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Grand’Maison F; Grammond P; Sola P; Ferraro D; Terzi M; Hupperts RMM; Alroughani R; Boz C; Shaygannejad V; Van Pesch V; Kappos L; Lechner-Scott J; Bergamaschi R; Turkoglu R; Solaro C; Ramo-Tello C; Iuliano G; Granella F; Van Wijmeersch B; Spitaleri DLA; Bolanos RF; Slee M; McCombe P; Prevost J; Ampapa R; Ozakbas S; Sanchez-Menoyo JL; Soysal A; Vucic OS; Petersen T; Verheul F; Butler E; Hodgkinson S; Sidhom Y; Gouider R; Cristiano E; Urtaza FJO; Saladino ML; Barnett M; Deri N; Moore F; Rozsa C; Yamout B; Skibina O; Gray O; Campbell J; Sempere A; Singhal B; Fragoso Y; Shaw C; Kermode A; Petkovska-Boskova T; Taylor B; Simo M; Vella N; Shuey N; Alkhaboori J; Al-Harbi T; Macdonell R; Dominguez JA; Kister I; Csepany T; Vrech C; Kovacs K; Sirbu CA; Hughes S; Sormani MP; Butzkueven H; Kalincik T, 2020, 'Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)', Neurology, 94, http://dx.doi.org/10.1212/wnl.94.15_supplement.2002

Butzkueven H; Spelman T; Madueno SE; Grand’Maison F; Kalincik T; Hodgkinson S; Skibina O; Butler E, 2020, 'Real-world experience of oral cladribine use in the MSBase Registry (3942)', Neurology, 94, http://dx.doi.org/10.1212/wnl.94.15_supplement.3942

Back to profile page